CN1584143A - Preparing method for growth factor slow-releasing system for tissue repair - Google Patents
Preparing method for growth factor slow-releasing system for tissue repair Download PDFInfo
- Publication number
- CN1584143A CN1584143A CN 200410048040 CN200410048040A CN1584143A CN 1584143 A CN1584143 A CN 1584143A CN 200410048040 CN200410048040 CN 200410048040 CN 200410048040 A CN200410048040 A CN 200410048040A CN 1584143 A CN1584143 A CN 1584143A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- beta
- poly
- tissue
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 239000003102 growth factor Substances 0.000 title claims description 36
- 230000017423 tissue regeneration Effects 0.000 title claims description 5
- 239000002121 nanofiber Substances 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 9
- 238000001523 electrospinning Methods 0.000 claims description 25
- 239000000835 fiber Substances 0.000 claims description 21
- 239000004745 nonwoven fabric Substances 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- -1 Sucrose fatty ester Chemical class 0.000 claims description 8
- 231100000252 nontoxic Toxicity 0.000 claims description 8
- 230000003000 nontoxic effect Effects 0.000 claims description 8
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 7
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 7
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000004814 polyurethane Substances 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 229920002988 biodegradable polymer Polymers 0.000 claims description 5
- 239000004621 biodegradable polymer Substances 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 238000009987 spinning Methods 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000003792 electrolyte Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- HTZOGMBRKCPHSZ-UHFFFAOYSA-N (3-ethylphenyl)methanamine;hydrochloride Chemical compound Cl.CCC1=CC=CC(CN)=C1 HTZOGMBRKCPHSZ-UHFFFAOYSA-N 0.000 claims description 2
- REKYPYSUBKSCAT-UHFFFAOYSA-N 3-hydroxypentanoic acid Chemical compound CCC(O)CC(O)=O REKYPYSUBKSCAT-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 210000001772 blood platelet Anatomy 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 238000007334 copolymerization reaction Methods 0.000 claims description 2
- 238000009795 derivation Methods 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 210000004153 islets of langerhan Anatomy 0.000 claims description 2
- 229940070765 laurate Drugs 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 claims description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 7
- 230000008439 repair process Effects 0.000 abstract description 2
- 241001234523 Velamen Species 0.000 abstract 1
- 239000002861 polymer material Substances 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 238000009418 renovation Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 23
- 239000003814 drug Substances 0.000 description 10
- 239000004744 fabric Substances 0.000 description 8
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004126 nerve fiber Anatomy 0.000 description 4
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 229920000520 poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102400000676 Chondromodulin-1 Human genes 0.000 description 1
- 101800004542 Chondromodulin-1 Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920003225 polyurethane elastomer Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Nonwoven Fabrics (AREA)
- Spinning Methods And Devices For Manufacturing Artificial Fibers (AREA)
- Artificial Filaments (AREA)
Abstract
The invention relates to electric filature to produce a kind of nano fiber growth gene slow-release system. This invention is compounded by biology decomposably polymer material and uses electric filature to produce a kind of nano fiber laxyly release system which contains growth gene. The method not only is operated easily and has a simple working procedure, but also can use the growth gene effectively in reducing the absent tissues. The laxly release system can emit growth gene steadily in body and avoids the lost of active of growth gene. More over, it can promote increasing of cells and tissue recovery. The production can not only be mad into the piece of velamen to transplant in the absent tissues for cure, but also be made into tissue engineering shelves to plant on cells and also be fostered out of body to increase cells for the tissue's renovation and then be transplanted in body to repair tissues.
Description
Technical field
The present invention relates to a kind of growth factor slow-release system that is used for tissue repair, specifically relate to a kind of method of utilizing the preparation of electrospinning silk technology to be loaded with the nanometer fiber slow-releasing system of growth factor.
Background technology
Growth factor is to have the protein matter of inducing and stimulating cellular proliferation, keeping biological effect such as cell survival, and it all has important facilitation to reparation and the regeneration that promotes cell proliferation, tissue or organ, and consequence is arranged in organizational project.But various growth factors all are polypeptide protein class materials, have water to exist and room temperature environment under be easy to lose biologically active.In direct injection body, growth factor will can't play the effect that long-term promotion defective tissue is repaired by disperse rapidly and degraded within one day.Therefore, how keeping and to prolong as far as possible the biologically active of growth factor under physical environment, is that growth factor can be real in the clinical key point that plays a role.
For solving the application problem of growth factor, medicine control slow release method can be introduced organizational project.Promptly utilize various growth factors of biodegradable polymer material load or hormone, quantitatively continue to discharge, thereby make growth factor can keep active for a long time, promote the growth and the differentiation of cell to seed cell.
The microsphere sustained-release system that is loaded with various growth factors has begun to be applied on the organizational project, and has obtained the certain promotion cell growth and the effect of propagation.General way is to make the microsphere sustained-release system that is loaded with growth factor earlier, is coated on the timbering material surface again, and operation is complicated, and does not reach good fixed effect, comes off easily.
But the electrospinning silk is the new technology of a kind of simple and effective ground preparation nanofiber.It is by applying high electric field generation injection stream to polymer solution or melt, and injection stream is through in the air, because the fluid instability produces the high speed whip and moves and quilt drawing-down rapidly, solvent evaporates or melt solidify simultaneously, and the formation diameter is at the fiber of 3～5000nm.Electricity spinning fibre has particularly been obtained a lot of application in the bio-medical field in field of functional materials, as tissue engineering bracket, wound dressing, operation barrier film etc.And in the medicament slow release field, electricity spinning fibre also has potential application prospect.Disclose a kind of electrospinning silk Processes and apparatus that utilizes multiple natural polymers or synthetic high polymer solution or fused solution to carry out spinning in the domestic application for a patent for invention " utilizing the electrospinning silk to prepare the method and the device of tissue engineering bracket material " (application number 03137309.7), thereby provide a kind of possibility for electrospinning silk technology is applied to organizational project.
Summary of the invention
The purpose of this invention is to provide a kind of electrospinning silk technology of utilizing and prepare the novel method that is loaded with the nanometer fiber slow-releasing system of growth factor, this method technology is simple, easy to operate; Utilize this method, not only can be made into the slowly-releasing diaphragm that is loaded with growth factor, implant, more can directly slow-releasing system be processed into tissue engineering bracket, reduce the activation procedure of tissue engineering bracket, improve the effective rate of utilization of growth factor with partner treatment; Make growth factor load capacity and rate of release adjustable extent wide, discharge stable.
The objective of the invention is to be achieved through the following technical solutions:
A kind of preparation method who is used for the growth factor slow-release system of tissue repair is characterized in that this method carries out as follows:
1) be jointly to be dissolved in the coordinative solvent of biological nontoxic at 1～100: 1 biodegradable polymer material and growth factor by mass ratio, being made into mass concentration is the electrospinning silk solution of 0.01-1g/mL;
2) in step 1), add the surfactant of biological nontoxic that mass concentration is 0-0.1g/mL and the electrolyte of 0-0.1g/mL, to regulate spinning properties;
3) use electrospinning silk technology, the solution electrospinning of above-mentioned preparation is become fiber, make the nano fiber non-woven fabric or the orientation fibers product that are loaded with growth factor.
Employed biodegradable polymer material comprises PHA class and copolymer thereof among the present invention, is selected from poly-beta-hydroxy-butanoic acid ester (PHB), poly-beta-hydroxy valerate (PHV), poly-beta-hydroxy capronate (PHHx); Polylactide (PLA), poly-glycolide (PGA), polycaprolactone (PCL) and Vicryl Rapide (PLGA); Protein-based, be selected from bovine serum albumin (BSA), collagen (Gellatin), gelatin; Polyvinyl alcohol (PVA); Shitosan (Chitosan) and derivative thereof; The degradable polyurethane class; Polycarbonate-based (PC); Or the blend of above-mentioned material.
Among the present invention employed growth factor comprise bone morphogenetic protein (BMP), transforming growth factor-beta 1 (TGF-β 1), basic fibroblast growth factor (bFGF), islet cells growth factor (IGF-1, IGF-2), vascular endothelial growth factor (VEGF), EGF (EGF), GGF (GGF), cartilage regulate element-I (ChM-I), blood platelet derivation growth factor (PDGF) or epithelial cells growth factor (KGF).
The surfactant of employed biological nontoxic comprises among the present invention: lauryl sodium sulfate (SDS); Oxirane and propylene oxide block copolymer; Aliphatic PPO-PEO copolymerization ethers; Lecithin; Polyethylene glycol; Sucrose fatty ester, as: stearic acid sucrose ester, laurate sucrose ester etc.
The electrolyte of employed biological nontoxic comprises among the present invention: the aliphatic quaternary ammonium salt, and as 3-ethyl benzyl ammonium chloride (TEBA), methyl tricaprylammonium chloride etc.
Method provided by the present invention compared with prior art, have the following advantages and the high-lighting effect: this method is simple to operate, and operation is easy, and growth factor is effectively utilized in the repairing and treating of defective tissue.Owing to medicine added carries out the nanofiber that the electrospinning silk obtains in the degradable polymer solution and have high specific area, the adjustable scope of drug loading and rate of releasing drug is big, and degraded along with polymeric material, the hole of fiber surface increases, rate of releasing drug can be improved, and has remedied the rate of releasing drug that the drug loading minimizing of fibrous inside institute is caused owing to drug thus and has reduced.Suitable as condition control, medicine can obtain stable zero level and discharge.And growth factor is wrapped in nano fiber scaffold inside, can also promote cell to breed to internal stent, thereby promotes the fusion between the cell and the secretion of extracellular matrix.Along with cell proliferation becomes tissue, after polymer support was degraded fully, the release of growth factor also finished thereupon, thereby can make the higher growth factor of cost obtain the most effective utilization.The prepared nanometer fiber slow-releasing system goods of the present invention are implanting tissue defect partner treatment directly, also availablely make various difform tissue engineering brackets, as be used for the tubular bracket of intravascular tissue engineering and nerve fiber engineering, the sheet support that is used for skin tissue engineering, cell and through in vitro culture in the plantation, make growth and proliferation of cell form tissue substituent, implant again with the repair deficiency tissue.
The specific embodiment
Degradable polyurethane class in the degradation material that the present invention uses is with reference to domestic patent of invention " a kind of polyurethane elastomer that contains the poly-beta-hydroxy-butyrate block synthetic " (application number 02129486.0).
Disclosed technology and equipment carries out in " utilizing the electrospinning silk to prepare the method and the device of tissue engineering bracket material " (application number 03137309.7) but of the electrospinning silk technology REFERENCE TO RELATED people that the present invention adopts application.
The product that uses this method to prepare both can be made into diaphragm and had implanted the tissue defect position with partner treatment, also can directly make various difform tissue engineering brackets, as be used for the tubular bracket of intravascular tissue engineering and nerve fiber engineering, be used for the sheet support of skin tissue engineering.
Following embodiment can further specify and explain operating process of the present invention and prescription thereof.
Embodiment 1:
(1) is that 4: 1 PLA and the mixture of BMP are dissolved in the ether with mass ratio, is made into the solution that concentration is 0.1g/mL, add the TEBA regulator solution electrical property of 0.01g/mL amount then;
(2) solution of joining is carried out the electrospinning silk, obtaining fibre diameter is the nano fiber non-woven fabric product of 800～1000nm;
(3) prepared nano fiber non-woven fabric is implanted fracture, fix, to promote union with bone screws.
Embodiment 2:
(1) is that 100: 1 PLA and the mixture of BMP are dissolved in the ether with mass ratio, is made into the solution that concentration is 0.01g/mL;
(2) solution of joining is carried out the electrospinning silk, obtaining fibre diameter is the nano fiber non-woven fabric product of 400～600nm;
(3) prepared nano fiber non-woven fabric is implanted fracture, fix, to promote union with bone screws.
Embodiment 3:
(1) is that 1: 1 PGA and the mixture of BMP are dissolved in the ether with mass ratio, is made into the solution that concentration is 0.5g/mL, add the TEBA and the 0.001g/mL lecithin regulator solution character of 0.1g/mL amount then;
(2) solution of joining is carried out the electrospinning silk, obtaining fibre diameter is the nano fiber non-woven fabric product of 1200～1500nm;
(3) prepared nano fiber non-woven fabric is implanted fracture, fix, to promote union with bone screws.
Embodiment 4:
(1) is that 40: 1 PHBV and the mixture of BMP are dissolved in the acetone with mass ratio, is made into the solution that concentration is 1g/mL, add 0.1g/mLSDS regulator solution character;
(2) solution of joining is carried out the electrospinning silk, obtaining fibre diameter is the nano fiber non-woven fabric product of 2000～2500nm;
(3) prepared nano fiber non-woven fabric is implanted fracture, fix, to promote union with bone screws.
Embodiment 5:
(1) is that 20: 20: 1 degradable PU, PHBV and the mixture of EGF are dissolved in 1 with mass ratio, in the 4-dioxane, is made into the solution that concentration is 0.2g/mL;
(2) solution of joining is carried out the electrospinning silk, fibre diameter be 1200～1400nm obtain the nano fiber non-woven fabric product;
(3) prepared nano fiber non-woven fabric is used as epidermal tissue's engineering rack.
Embodiment 6:
(1) is that 6: 1 degradable PU and the mixture of EGF are dissolved in 1 with mass ratio, in the 4-dioxane, is made into the solution that concentration is 0.3g/mL;
(2) solution of joining is carried out the electrospinning silk, obtaining fibre diameter is the nano fiber non-woven fabric product of 1300～1600nm;
(3) prepared nano fiber non-woven fabric is used as epidermal tissue's engineering rack.
Embodiment 7:
(1) is that 50: 1 degradable PU and the mixture of VEGF are dissolved in 1 with mass ratio, in the 4-dioxane, is made into the solution that concentration is 0.4g/mL;
(2) solution of joining is carried out the electrospinning silk, with the rotation receiving system, obtain fibre diameter and be 1500～1800nm, diameter is a 1cm tubular nanometer fabric nonwoven cloth;
(3) prepared tubulose nonwoven fabric is used as the intravascular tissue engineering support.
Embodiment 8:
(1) is that 20: 1 collagen and the mixture of VEGF are dissolved in 1 with mass ratio, in the 4-dioxane, is made into the solution that concentration is 0.05g/mL;
(2) solution of joining is carried out the electrospinning silk, with the rotation receiving system, obtain fibre diameter and be 70～100nm, diameter is the tubular nanometer fabric nonwoven cloth of 1.5cm;
(3) prepared tubulose nonwoven fabric is used as the intravascular tissue engineering support.
Embodiment 9:
(1) is that the mixture of 10: 20: 1 gelatin, collagen and GGF is dissolved in 1 with mass ratio, in the 4-dioxane, is made into the solution that concentration is 0.3g/mL;
(2) solution of joining is carried out the electrospinning silk, with the rotation receiving system, obtain fibre diameter and be 150～200nm, diameter is the tubular nanometer fabric nonwoven cloth of 5mm;
(3) prepared tubulose nonwoven fabric is used as the nerve fiber engineering rack.
Embodiment 10:
(1) is that the mixture of 1: 5: 1 gelatin, collagen and GGF is dissolved in 1 with mass ratio, in the 4-dioxane, is made into the solution that concentration is 0.2g/mL;
(2) solution of joining is carried out the electrospinning silk, with the rotation receiving system, obtain fibre diameter and be 110～140nm, diameter is the tubular nanometer fabric nonwoven cloth of 5mm;
(3) prepared tubulose nonwoven fabric is used as the nerve fiber engineering rack.
Claims (4)
1. preparation method who is used for the growth factor slow-release system of tissue repair, it is characterized in that: this method is carried out as follows:
1) be jointly to be dissolved in the coordinative solvent of biological nontoxic at 1～100: 1 biodegradable polymer material and growth factor by mass ratio, being made into mass concentration is the electrospinning silk solution of 0.01-1g/mL;
2) in step 1), add the surfactant of biological nontoxic that mass concentration is 0-0.1g/mL and the electrolyte of 0-0.1g/mL, to regulate spinning properties;
3) use electrospinning silk technology, the solution electrospinning of above-mentioned preparation is become fiber, make the nano fiber non-woven fabric or the orientation fibers product that are loaded with growth factor.
2. according to the described preparation method of claim 1, it is characterized in that: described biodegradable polymer material comprises PHA class and copolymer thereof, is selected from poly-beta-hydroxy-butanoic acid ester, poly-beta-hydroxy valerate and poly-beta-hydroxy capronate; The copolymer of polylactide, poly-glycolide, polycaprolactone and glycolide and lactide; Protein-based, be selected from bovine serum albumin, collagen, gelatin; Polyvinyl alcohol; Shitosan and derivative thereof; The degradable polyurethane class; The blend of polycarbonate-based or above-mentioned material; Described growth factor comprises: bone morphogenetic protein, transforming growth factor-beta 1, basic fibroblast growth factor, islet cells growth factor, vascular endothelial growth factor, EGF, GGF, cartilage are regulated element-I, blood platelet derivation growth factor or epithelial cells growth factor.
3. according to the described preparation method of claim 1, it is characterized in that: the surfactant of described biological nontoxic comprises: lauryl sodium sulfate; Oxirane and propylene oxide block copolymer; Aliphatic PPO-PEO copolymerization ethers; Lecithin; Polyethylene glycol; Sucrose fatty ester is selected from stearic acid sucrose ester and laurate sucrose ester.
4. according to the described preparation method of claim 1, it is characterized in that: the electrolyte of described biological nontoxic adopts the aliphatic quaternary ammonium salt, is selected from 3-ethyl benzyl ammonium chloride and methyl tricaprylammonium chloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410048040 CN1267590C (en) | 2004-06-11 | 2004-06-11 | Preparing method for growth factor slow-releasing system for tissue repair |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410048040 CN1267590C (en) | 2004-06-11 | 2004-06-11 | Preparing method for growth factor slow-releasing system for tissue repair |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1584143A true CN1584143A (en) | 2005-02-23 |
| CN1267590C CN1267590C (en) | 2006-08-02 |
Family
ID=34602058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410048040 Expired - Fee Related CN1267590C (en) | 2004-06-11 | 2004-06-11 | Preparing method for growth factor slow-releasing system for tissue repair |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1267590C (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101906459A (en) * | 2010-07-27 | 2010-12-08 | 北京师范大学 | Method for testing toxicity of phenols in water by immobilizing cells with electrostatic spinning fibrous membrane |
| CN102488929A (en) * | 2011-12-16 | 2012-06-13 | 东华大学 | Regenerated silk fibroin tissue engineering scaffold containing vascular endothelial growth factor and preparation method thereof |
| CN102965838A (en) * | 2012-12-11 | 2013-03-13 | 青岛大学 | Method for preparing micro-nano fiber film by electrostatic spinning method |
| CN103394119A (en) * | 2013-07-10 | 2013-11-20 | 中国人民解放军第四军医大学 | Method for preparing nanometer bionic slow release biomedical dressing by electrostatic spinning |
| CN103596553A (en) * | 2011-04-11 | 2014-02-19 | 感应生物制品股份有限公司 | System and method for multiphasic release of growth factors |
| CN104614510A (en) * | 2007-05-10 | 2015-05-13 | 阿索尔达治疗公司 | Methods for detecting cardiac damage |
| CN104774762A (en) * | 2015-03-31 | 2015-07-15 | 苏州睿研纳米医学科技有限公司 | Oriented polymer nanometer fibrocyte culture plate and preparation method thereof |
| CN105420848A (en) * | 2015-11-25 | 2016-03-23 | 中国纺织科学研究院 | Superfine polyglycollide fiber and preparation method and device, application and patch thereof |
| CN106730038A (en) * | 2017-01-12 | 2017-05-31 | 广东泰宝医疗器械技术研究院有限公司 | A kind of tunica fibrosa for tracheae soft tissue repair and preparation method thereof |
| CN107012526A (en) * | 2017-06-01 | 2017-08-04 | 合肥创沃科技有限公司 | A kind of preparation method of the composite regenerated fiber repair materials of Goat Placenta |
| CN108498846A (en) * | 2018-05-11 | 2018-09-07 | 南通大学 | A kind of slow-release chitosan antiseptic dressing and preparation method thereof |
| CN108904888A (en) * | 2018-07-10 | 2018-11-30 | 南方医科大学 | The method that method of electrostatic spinning preparation carries Pravastatin intravascular tissue engineering stent material |
| CN111714248A (en) * | 2020-05-08 | 2020-09-29 | 南开大学 | Vascular stent for promoting rapid cell proliferation and extracellular matrix deposition and acellular matrix artificial blood vessel |
-
2004
- 2004-06-11 CN CN 200410048040 patent/CN1267590C/en not_active Expired - Fee Related
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10258667B2 (en) | 2007-05-10 | 2019-04-16 | Acorda Therapeutics, Inc. | Methods for detecting cardiac damage |
| US9757429B2 (en) | 2007-05-10 | 2017-09-12 | Acorda Therapeutics, Inc. | Methods for detecting cardiac damage |
| CN104614510A (en) * | 2007-05-10 | 2015-05-13 | 阿索尔达治疗公司 | Methods for detecting cardiac damage |
| CN104614510B (en) * | 2007-05-10 | 2017-07-04 | 阿索尔达治疗公司 | The method for detecting heart injury |
| US11071770B2 (en) | 2007-05-10 | 2021-07-27 | Acorda Therapeutics, Inc. | Methods for detecting cardiac damage |
| CN101906459A (en) * | 2010-07-27 | 2010-12-08 | 北京师范大学 | Method for testing toxicity of phenols in water by immobilizing cells with electrostatic spinning fibrous membrane |
| CN101906459B (en) * | 2010-07-27 | 2011-12-07 | 北京师范大学 | Method for testing toxicity of phenols in water by immobilizing cells with electrostatic spinning fibrous membrane |
| CN103596553A (en) * | 2011-04-11 | 2014-02-19 | 感应生物制品股份有限公司 | System and method for multiphasic release of growth factors |
| CN102488929A (en) * | 2011-12-16 | 2012-06-13 | 东华大学 | Regenerated silk fibroin tissue engineering scaffold containing vascular endothelial growth factor and preparation method thereof |
| CN102965838A (en) * | 2012-12-11 | 2013-03-13 | 青岛大学 | Method for preparing micro-nano fiber film by electrostatic spinning method |
| CN103394119A (en) * | 2013-07-10 | 2013-11-20 | 中国人民解放军第四军医大学 | Method for preparing nanometer bionic slow release biomedical dressing by electrostatic spinning |
| CN104774762A (en) * | 2015-03-31 | 2015-07-15 | 苏州睿研纳米医学科技有限公司 | Oriented polymer nanometer fibrocyte culture plate and preparation method thereof |
| CN105420848A (en) * | 2015-11-25 | 2016-03-23 | 中国纺织科学研究院 | Superfine polyglycollide fiber and preparation method and device, application and patch thereof |
| CN106730038A (en) * | 2017-01-12 | 2017-05-31 | 广东泰宝医疗器械技术研究院有限公司 | A kind of tunica fibrosa for tracheae soft tissue repair and preparation method thereof |
| CN107012526A (en) * | 2017-06-01 | 2017-08-04 | 合肥创沃科技有限公司 | A kind of preparation method of the composite regenerated fiber repair materials of Goat Placenta |
| CN108498846A (en) * | 2018-05-11 | 2018-09-07 | 南通大学 | A kind of slow-release chitosan antiseptic dressing and preparation method thereof |
| CN108904888A (en) * | 2018-07-10 | 2018-11-30 | 南方医科大学 | The method that method of electrostatic spinning preparation carries Pravastatin intravascular tissue engineering stent material |
| CN108904888B (en) * | 2018-07-10 | 2021-03-23 | 南方医科大学 | Method for preparing pravastatin-loaded vascular tissue engineering scaffold material by electrostatic spinning method |
| CN111714248A (en) * | 2020-05-08 | 2020-09-29 | 南开大学 | Vascular stent for promoting rapid cell proliferation and extracellular matrix deposition and acellular matrix artificial blood vessel |
| CN111714248B (en) * | 2020-05-08 | 2024-06-14 | 南开大学 | Vascular stent for promoting rapid proliferation of cells and promoting deposition of extracellular matrix of vascular stent, and acellular matrix artificial blood vessel |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1267590C (en) | 2006-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rahmati et al. | Electrospinning for tissue engineering applications | |
| Wu et al. | Resorbable polymer electrospun nanofibers: History, shapes and application for tissue engineering | |
| Venugopal et al. | Interaction of cells and nanofiber scaffolds in tissue engineering | |
| Wang et al. | Stem cell-based tissue engineering with silk biomaterials | |
| Woodruff et al. | The return of a forgotten polymer—Polycaprolactone in the 21st century | |
| CN1267590C (en) | Preparing method for growth factor slow-releasing system for tissue repair | |
| CN1568903A (en) | Composite scaffolds seeded with mammalian cells | |
| Zamani et al. | Recent advances in cell electrospining of natural and synthetic nanofibers for regenerative medicine | |
| KR20140090704A (en) | Artificial dura mater and manufacturing method thereof | |
| CN102277737A (en) | Preparation method and application of polycaprolactone/natural high-molecular composite porous scaffold | |
| JP2006501949A (en) | Sealant for skin and other tissues | |
| JP2004243125A (en) | Implantable medical device seeded with mammalian cell and method of treatment | |
| US20130177623A1 (en) | Preparation Rich in Growth Factor-Based Fibrous Matrices for Tissue Engeering, Growth Factor Delivery, and Wound Healling | |
| CN103006359A (en) | Bionic three-dimensional tissue engineering scaffold and preparation method thereof | |
| CN105457096A (en) | Preparation methods of degradable tussah fibroin tissue engineering scaffold material with good biocompatibility | |
| US20190060517A1 (en) | Scaffold for cardiac patch | |
| CN103127548B (en) | Manufacture method of artificial nerve conduit for promoting nerve defect repair | |
| Ko et al. | Growth behavior of endothelial cells according to electrospun poly (D, L-lactic-co-glycolic acid) fiber diameter as a tissue engineering scaffold | |
| Zha et al. | Electrospun natural polymer and its composite nanofibrous scaffolds for nerve tissue engineering | |
| Kanmaz et al. | Electrospun polylactic acid based nanofibers for biomedical applications | |
| CN109381732A (en) | Electrostatic spinning dressing, preparation method and the application of growth factor-loaded micromolecular inhibitor | |
| Wang et al. | Aligned biomimetic scaffolds as a new tendency in tissue engineering | |
| CN1569236A (en) | Implantable pouch seeded with insulin-producing cells to treat diabetes | |
| CN109663142B (en) | Drug-loaded degradable surgical sewing thread and preparation method thereof | |
| Hoque et al. | Electrospun matrices from natural polymers for skin regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060802 |